Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cedazuridine and Decitabine in Solid Tumors
NCT03875287Phase 1Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2019
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cedazuridine and decitabine in solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Adverse Events at 2 years and Maximum Tolerated Dose at 2 years. Started Apr 2019; status: active, not recruiting.
02
Drugs
cedazuridinedecitabine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03875287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875287.